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Abstrak
Tujuan Untuk menyusun konstruksi tissue microarrays (TMAs) dan mengevaluasi level reseptor androgen pada 
perkembangan kanker prostat dengan pemeriksaan imunohistokimia pada jaringan prostat tikus model the transgenic 
adenocarcinoma of mouse prostate (TRAMP) dan tikus non transgenik.          
Metode Konstruksi tissue microarrays (TMAs) dilakukan terhadap sampel yang berasal dari lobus dorso-lateral 
tikus kelompok kontrol (non-transgenic), kelompok tanpa kastrasi (intact TRAMP) dan kelompok kastrasi (castrated 
TRAMP) yang di pulas dengan haematoxylin eosin (H&E). Ekspresi reseptor androgen dievaluasi pada sampel TMAs 
dengan video image anlysis (VIA). 
Hasil Ekspresi reseptor androgen dijumpai pada jaringan prostat normal maupun patologis baik pada lesi non-neo-
plastik maupun neoplastik sampai lesi ganas, sedangkan pada kanker prostat stadium lanjut ekspresi menurun atau 
menghilang. Ekspresi reseptor androgen meningkat pada kelompok kastrasi (kondisi pelucutan androgen) dibanding 
pada kelompok tanpa kastrasi.  
Kesimpulan Sama seperti pada manusia, pada tikus TRAMP kanker prostat menunjukkan variasi ekspresi AR sampai 
kondisi castrate resistant, yang menunjukkan bahwa AR turut memfasilitasi pertumbuhan tumor lebih lanjut. (Med J 
Indones 2010; 19:5-13)
Abstract
Aim To construct tissue microarrays (TMAs) that consisted of prostate tumours from the transgenic adenocarcinoma of 
mouse prostate (TRAMP) mice and non-transgenic murine prostates and to assess androgen receptor (AR) levels during 
progression of prostate cancer in TRAMP mice by immunohistochemistry.
Methods Haematoxylin and eosin (H&E) sections from the ventral and dorso-lateral prostate lobes of non-transgenic, intact 
TRAMP and castrated TRAMP were used to demarcate regions of interest for TMAs construction. The samples on TMAs 
were used to evaluate AR expression using video image analysis (VIA).
Results AR was expressed during cancer progression, but AR levels were reduced or absent in late stage disease. Further-
more, when AR levels were compared in tumours from intact and castrate animals, a significant increase in AR levels was 
observed following androgen ablation.  
Conclusion Similar to clinical prostate cancer, in the TRAMP model, prostate tumours evolve mechanisms to maintain AR 
expression and AR responsive gene pathways following castration to facilitate continued tumour growth. (Med J Indones 
2010; 19:5-13)
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Prostate cancer is the second most common malignant 
disease in men from Western communities and is the 
second highest cause of cancer related deaths in men.1 
A critical issue in prostate cancer is the mechanism of 
failure of androgen ablation therapy (AAT), which is 
the only accepted systemic treatment for metastatic 
disease. While there is a very good response to AAT in 
about 90% of patients, the disease eventually relapses 
and progresses to castrate resistance.2,3
Castrate resistant prostate cancer is incurable and 
therefore is responsible for the majority of prostate 
cancer related deaths. While the underlying mechanisms 
of this conversion from hormone responsive to castrate 
resistant remain unknown, some mechanisms are 
emerging. Several studies have identified that the 
androgen receptor (AR), a critical component of the 
androgen signalling pathway, is expressed in both 
androgen-sensitive and castrate resistant prostate 
cancers. It is most likely that the AR continues to 
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play an important role in prostate cancer progression, 
following failure of AAT.4,5
Investigation of the continuing role of AR signalling 
pathways in the progression of prostate cancer following 
AAT is limited by the availability to obtain clinical 
specimens representative of castrate resistant metastatic 
disease. Consequently, there has been considerable interest 
in the development of animal models that closely mimic 
the clinical disease. The transgenic adenocarcinoma of 
mouse prostate (TRAMP) model is uniquely suited to 
elucidate how the regulation of the androgen-signalling 
axis contributes to the progression of prostate cancer, as in 
TRAMP model, tumours arise spontaneously and follow 
a progression similar to that seen in humans.6
The aims of this research were 1) to construct tissue 
microarrays (TMAs) that contained prostate tumours 
that were collected from TRAMP mice and non-
transgenic murine prostates and 2) to assess AR levels 
during progression of prostate cancer in TRAMP mice 
within the TMAs by immunohistochemistry.
METHODS
A cohort study on a TRAMP model was carried out from 
January to December 2005 in Dame Roma Mitchell 
Cancer Research Laboratories, Hanson Institute, 
University of Adelaide, South Australia. 
Animal cohorts and tumour grading
Female TRAMP mice, maintained in a pure C57BL/6 
background (Harlan Sprague Dawley, Inc., Indianapolis 
IN), were crossed with male non-transgenic FVB 
mice (Harlan Sprague Dawley, Inc., Indianapolis IN). 
[C57BL/6 TRAMP x FVB] F1 males non-transgenic 
and transgenic were generated from this cross. 
Transgenic mice were identified by a PCR-based 
screening assay using mouse tail DNA with primers as 
previously described. 6 The TRAMP mice were divided 
into 2 cohorts:1) intact or non-castrated TRAMP mice, 
and 2) castrated TRAMP mice. A group of intact non-
transgenic littermate mice were used as a control group. 
The non-transgenic and the intact TRAMP mice were 
divided into the following age groups: 8, 10, 12, 14, 
16, 18, 20, 22, 24, 26, and 30 weeks. Intact TRAMP 
mice in which tumours were macroscopically visible 
and the lobes indistinguishable were separated into a 
sub-cohort of intact TRAMP mice with macroscopic 
tumours and analysed separately. The mice from this 
cohort were sacrificed at following time points: 16, 
18, 20, 22, 24, 26, and 28 weeks. Castrated TRAMP 
mice were castrated at 12 weeks of age, when prostate 
intra-epithelial neoplasia (PIN) is expected to develop, 
and designated as the castrated TRAMP mouse cohort. 
The mice were palpated on abdominal areas throughout 
prostate tumour development and the tumours from 
mice that were visible without palpitation were obtained 
by scarifying the mice at 18, 20, 22, 24, 26, 28 and 30 
weeks. Prior to sacrifice each mouse was anesthetised. 
Metastatic lesions were also harvested. All collected 
tissues were fixed in 10% formalin, embedded in paraffin 
blocks, and stained with haematoxylin and eosin (H&E). 
All prostatic tissues were histologically evaluated and graded 
by examining the H&E sections under a light microscope 
according to an established pathology classification for 
genetically engineered mouse (GEM), which was also used 
to classify the pathology of prostate tumours in the present 
study.7 The pathological grading was assessed and analysed 
in both the dorso-lateral and ventral prostate and reviewed 
by two pathologists (KM and JS).
Construction of tissue microarray blocks
The analysed H&E stained sections were used for the 
histopathology assessment and to demarcate regions of 
tissue of interest for the construction of a TMA block 
as previously describe.8 In this study we used 1.0 mm 
needles and 1.5 mm needles for larger tissues. Three 
orientation cores from mouse testis were placed in 
specific positions outside the geometric margins of the 
usually square or rectangular arrays to orient the whole 
microarray sections after they have been cut and also as 
positive controls for AR immunohistochemistry.     
Androgen receptor immunohistochemistry
The TMA blocks were cut at 4 µm sections then 
deparaffinized in xylene and sequentially rehydrated. 
Endogenous peroxide activity was quenched by 
incubating the slides with hydrogen peroxide. Complete 
antigen retrieval was carried out by microwaving the 
slides in 10 mM citrate buffer (pH 6.5), the slides were 
then incubated in a blocking solution. Further, the slides 
were incubated with sheep polyclonal AR antibody 
(U402-S; affinity purified rabbit antisera generated 
against amino acids 1 to 21 of the human AR) (made 
in Dame Rome Mitchel Cancer Research Laboratory, 
Australia) overnight. The slides were then subsequently 
washed in phosphate buffered saline (PBS) and incubated 
with secondary antibody, a 1/400 dilution of a biotinylated 
sheep anti-rabbit (Dako, Denmark) in blocking solution, 
followed by strepavidin horseradish complex (Dako, 
Denmark) (1/500 dilution in PBS). To generate a brown-
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insoluble deposit, slides were incubated with a mixture 
of diaminobenzidine tetrahydrochloride (DAB) (50 mg/
ml) and hydrogen peroxide (0.06%). Sections were 
counterstained with weak Lillie-Mayer haematoxylin 
(1/10 dilution of strong haematoxylin), dehydrated in 
sequential absolute ethanol, cleared with xylene and 
mounted under glass cover slips. 
Androgen receptor immunostaining quantification
Androgen receptor immunostaining quantification was 
done by video image analysis (VIA) and visual scoring.
Video image analysis 
An Olympus BH-2 light microscope was connected 
to a computer-assisted colour image system (Video 
Pro 32 [R] Leading Edge Pty. Ltd., Adelaide South 
Australia) was used to examine AR immunostaining. 
All available glandular tissue containing tissue 
areas from TMA cores were captured using a digital 
camera under bright field microscopy at 40x objective 
magnification. An average of 10 images per section 
were randomly captured and analysed. The VIA 
measurements were restricted to the prostate glandular 
cell nuclei of normal glands, hyperplasia, PIN (without 
and with progression), adenocarcinomas either well 
differentiated (WD), moderately differentiated (MD) or 
poorly differentiated (PD) and metastatic tissues from 
lymph nodes. Measurements were done on the total 
area of analysed tissues (both positively and negatively 
stained nuclei) and the positively stained nuclei for an 
average 10 fields per triplicate cores. Every field was 
examined with a constant threshold setting for all fields 
using two wavelength interference filters, i.e. 550 nm 
and 436 nm. The 550 nm filter was used to detect the 
present nuclei total number that covered the whole 
nuclear area and the 436 nm filter was used to detect 
and cover all DAB stained nuclei (brown area). Three 
parameters were measured for every section: (1) the 
integrated optical density per field (IOD) as an average 
µm of the optical densities for every positively stained 
pixel for 10 field sections, (2) the percentage of AR 
positive nuclei (DAB area per total area) multiplied by 
100, and (3) the mean optical density (MOD), which is 
the IOD per area of DAB staining (brown area). 
The AR immunostaining was quantitated using VIA in 
the different lobes of the non-transgenic control mice 
and in all identified lesions in the intact and castrated 
TRAMP mice. 
Visual scoring
To achieve consistency, the same images used for VIA 
were visually scored by an independent person who was 
unaware of the diagnosis and VIA scores. Results for 
AR immunoreactivity were represented as a percentage 
of positively stained nuclei per image field. From each 
section at least ten images were randomly taken and the 
percentage was averaged
Data analysis 
Fisher’s exact test was used to compare the differences 
in metastatic incidence between intact and castrated 
TRAMP mice. The differences in AR positive staining 
between the ventral and dorso-lateral lobes in the non-
transgenic group, and the differences in AR staining 
in intact and castrated TRAMP macroscopic cohorts 
were compared using Wilcoxon ranked test. Moreover, 
Mann-Whiney-U test was performed to compare the 
AR staining in macroscopic tumour cohorts of castrated 
TRAMP and intact TRAMP mice, also to compare the 
AR staining in metastatic groups of castrated TRAMP 
and intact TRAMP mice. All analyses were performed 
with Statistical Product and Service Solutions (SPSS 
Version 11.5.0 Copyright 2004, SPSS Inc.). Data was 
accepted as statistically significant when P < 0.05. 
RESULTS
Histological features of every cohort can be seen on 
table 1. 
Androgen receptor  expression
In this study, 207 tissue samples were analysed (Table 1), 
and from that number, 123 tissue samples were transferred 
into triplicate cores of TMA blocks then immunostained 
with AR. A total of 76% of the tissue samples (94 out of 
123) were able to be analysed, 23 of which were normal, 
10 were hyperplasia, 15 were PIN without progression, 4 
were PIN with progression, 2 were WD adenocarcinoma, 2 
were MD adenocarcinoma, 31 were PD adenocarcinoma, 
and 7 were metastatic PD adenocarcinoma. In 24 % of 
cases (29 out of 123) no data was available due to specific 
tissue loss as a result of the antigen retrieval procedures or 
three-dimensional changes in the tissue core arrangement, 
including tissue damage or folding.
In the ventral and dorso-lateral lobes of intact TRAMP 
mice, the full spectrum of pathology were identified. 
Intact TRAMP mice with macroscopic tumours 
showed WD and PD adenocarcinomas, while castrated 
TRAMP mice showed 100% PD adenocarcinoma. The 
incidence of metastases in castrated TRAMP mice was 
higher than those in intact TRAMP mice.
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Androgen receptor expression in non-transgenic mice
In the prostate of non-transgenic mice, nuclear AR 
immunoreactivity was observed in the majority of epithelial 
and stromal cells. This AR expression was heterogenous 
even though most of the sections were normal (Figures 
1 A and B). We also observed that AR expression was 
heterogenous in the different prostatic lobes. 
Androgen receptor expression in intact TRAMP mice
In intact TRAMP mice, AR expression was identified 
in the nuclei of normal, hyperplasia, PIN, and WD 
adenocarcinoma prostate cells (Figures 1 B-F). Further, 
AR expression was variable in the two MD tumours. In 
PD adenocarcinoma, where normal glands were trapped 
among cancer cells, a difference in AR expression was 
observed. The expression of AR in normal trapped 
glands showed strong intensity while the adjacent cancer 
cells showed variable weak to negative AR expression 
(Figure 1 G). Moreover, PD adenocarcinoma sections 
of localised prostatic lobes (n= 4) demonstrated 
various weak to negative AR expression compared to 
non-tumour lesions and WD to MD adenocarcinoma. In 
addition, AR expression in the prostates of mice with PD 
macroscopic tumours also varied from weak to negative 
regardless of the mouse age.
Androgen receptor expression in metastatic samples
In metastatic prostate tumour samples, AR expression 
was also variable weak to negative in the majority of 
sections either from intact or castrated TRAMP mice.
PIN= prostate intra-epithelial neoplasia, WoP= without progression, WP= with progression, WD= well differentiated, AC= adenocarcinoma, MD= 
moderately differentiated, PD= poorly differentiated, V= ventral, DL= dorso-lateral
Table 1. Classification of prostate pathologic progression in non-transgenic mice, intact and castrated TRAMP model. 
Classification of 
pathology progression


















































MD AC 0 0 0 2
(3%)
0 0
PD AC 0 0 7 (12%) 4 (6%) 26 (96%) 21 (100%)
Total 16 17 61 65 27 21
Total Metastasis 18/27 (67%) 18/21 (86%)






































Normal Hyperplasia PIN WoP PIN WP WD MD PD
Figure 2. Average AR score by VIA in non-transgenic mice 
Figure 3. Average AR scores by VIA in ventral and dorso-lateral 
lobes of microscopic lesions of intact TRAMP mice.
PIN WoP= PIN without progression, PIN WP= PIN with progression, 
























Figure 4. Average AR scores in the prostate lobe of intact and 
castrated TRAMP mice with macroscopic and meta-
static tumours. 
Figure 1. AR expression in various pathology lesions from non-transgenic, intact TRAMP and castrated TRAMP mice. A. In the 
normal prostate gland. B. In hyperplasia of intact TRAMP mouse. C. In PIN with progression from an intact TRAMP 
mouse. D. In WD tumour from an intact TRAMP mouse. E. In MD adenocarcinoma from an intact TRAMP mouse. F. In 
PD tumour section from an intact TRAMP mouse. G. Heterogenous AR expression on PD tumour from a castrated TRAMP 



























Figure 5. Average visual AR scores in non-transgenic mice






















Figure 6. The average visual AR scores in the ventral and dorso-
lateral lobes of intact TRAMP mice
PIN WoP= PIN without progression, PIN WP= PIN with progression, 
WD= well differentiated, MD= moderately differentiated, PD= poorly 
differentiated

























Figure 7. Average visual AR scores in intact and castrated TRAMP 
mice with macroscopic and metastatic tumours
Androgen receptor expression in castrated TRAMP mice
All sections from this cohort exhibited PD adenocarcinomas 
and AR expression that was heterogenous. The majority of 
sections showed variable weak to negative AR expression 
regardless of the age of the mice (Figure 1 H). Areas that 
displayed a small cell carcinoma variant showed weak to 
negative AR expression (Figures 1 J-L). In a few sections, 
some areas showed weak AR expression both in the nuclei 
and cytoplasms (Figures 1 J and L). 
Quantification of AR immunostaining using VIA
Non-transgenic mice
The average AR score in non-transgenic mice showed 
a significant difference between the ventral and dorso-
lateral lobes. The average AR score in the ventral lobe was 
higher than in dorso-lateral lobe (P= 0.012) (Figure 2).
Intact TRAMP mice with microscopic lesions
In this cohort, no difference in AR score pattern between 
the ventral and dorso-lateral lobes was observed (Figure 
3). In the ventral lobe, the average AR score in normal (n= 
1), hyperplasia (n= 3), PIN without progression (n= 5), 
PIN with progression (n= 2), and WD adenocarcinoma 
(n= 1), showed consistently higher average AR scores 
than observed in the PD adenocarcinoma (n= 3) (Figure 
3).  In the dorso-lateral lobes, the average AR scores 
in normal (n= 1), hyperplasia (n= 6), PIN without 
progression (n= 7), PIN with progression (n= 2) and 
MD adenocarcinoma (n= 2) showed relatively similar 
AR scores. However, the average AR score in PD 
adenocarcinoma (n= 1) significantly decreased compared 
to other lesions (Figure 3). 
Mice with macroscopic tumours and metastatic lesions
The average AR imunostaining in the prostates of 
castrated TRAMP mice with macroscopic tumours (n= 
14) was significantly increased compared to the average 
of AR immunostaining scores in intact TRAMP mice 
(n= 13). There was a significant difference of AR score 
between castrated and intact TRAMP mice without 
metastatic tumours (P = 0.000). In contrast, the average 
AR staining in metastatic groups showed no difference 
(P = 0.857) between castrated (n= 4) and intact TRAMP 
(n= 3) mice (Figure 4).
Visual Scoring
Non-transgenic mice
Wilcoxon signed ranks test showed that the average 
visual AR scores in non-transgenic mice were 
significantly different between the ventral and dorso-
lateral lobes, with AR scores being higher in the ventral 
lobe compared to the dorso-lateral lobe (P = 0.012) 
(Figure 5). This is consistent with the measurement 
made using VIA. 
Intact TRAMP mice with microscopic lesions
In intact TRAMP mice with microscopic lesions no 
difference in the AR score of the ventral and dorso-
lateral lobes and in the pattern of both lobes were 
observed (Figure 6). In the ventral lobe, the average 
AR scores in normal (n= 1), hyperplasia (n= 3), PIN 
without progression (n= 5), PIN with progression (n= 
2), and WD adenocarcinoma (n= 1), showed relatively 
similar AR scores. However, the average AR score in 
PD adenocarcinoma (n= 3) was decreased compared to 
the other lesions. 
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In the dorso-lateral lobe, the average AR scores 
in normal (n= 1), hyperplasia (n= 5), PIN without 
progression (n= 7), PIN with progression (n= 2), and 
MD adenocarcinoma (n= 2) showed relatively similar 
AR score. Similarly to that observed in the ventral lobe, 
the average AR score in PD adenocarcinoma (n= 1) was 
decreased compared to the other lesions (Figure 6). 
Macroscopic tumours in TRAMP mice with metastatic 
tumours  
The average visual AR imunostaining scores in castrated 
TRAMP mice with macroscopic tumours (n= 14) was 
significantly increased (P= 0.027) compared to the average 
of AR scores in intact TRAMP mice with macroscopic 
tumours (n= 13). The visual AR staining in metastatic 
group, however, showed no difference between castrated 
and intact TRAMP mice (P= 0.857) (Figure 7).
DISCUSSION
A critical issue in human prostate cancer is the rapid 
progression of the disease after failure of AAT, indicative 
of castrate resistant tumour growth. Resistance to AAT 
is not necessarily due to loss of androgen sensitivity of 
the tumour cells, but may develop as a consequence of 
a deregulated androgen-signalling axis resulting from 
increased sensitivity of AR activation or structural 
alterations in the AR gene.4   Thus it appears that prostate 
cancers evolve mechanisms to maintain AR expression 
and AR responsive gene pathways following AAT, 
and these mechanisms play a key role in the failure 
of AAT. Furthermore, AR heterogeneity is often seen 
in human prostate cancer and has been proposed as a 
prognostic factor for hormonal therapy.9-12 Therefore, 
AR immunochemistry was used to determine the AR 
status in the TRAMP mice. Previous studies suggested 
2 assessments to be performed; computerised video 
image analysis (VIA) and visual examination. 
Computerized VIA objectively quantitates AR, while 
visual examination is more subjective. 9 
Preliminary studies using the TRAMP model showed 
that AR staining was expressed in the nuclei of luminal 
epithelial cells and that expression was heterogenous 
in the stromal compartment of the mouse prostate. In 
contrast, the AR exhibits weak or no staining in the 
majority of MD or PD prostate cancer. 6,13-15
In comparison, a study of human prostate cancer 
demonstrated that there was a considerable increase in 
the heterogeneity of AR immunostaining in prostate 
cancer cells compared to non-malignant lesions. 16 Other 
studies have found that normal prostate cells exhibit 
greater homogeneity of AR immnunostaining.11,17 
Furthermore, a study  identified that AR was expressed 
both in relapsed and metastatic prostate cancer.18 
Similar to previous data in the human prostate and 
TRAMP mouse prostate, in the present study we 
observed that AR was expressed throughout non-
malignant prostate lesions in addition to WD and 
MD adenocarcinomas. We also observed that the AR 
exhibited weak or no expression in PD prostate cancers 
from either PD primary or metastatic adenocarcinoma. 
Taken together, AR immunostaining in the TRAMP 
model demonstrated similar AR expression patterns to 
human prostate tissues.
The use of VIA enables quantification of AR 
levels detected by immunohistochemistry. The AR 
immunostaining can be used to predict response to 
endocrine therapy and prostate cancer patient survival. 
10,11,19 Moreover, data from Ricciardelli et al. (2005) 
showed that the assessment of AR levels and its cellular 
distribution can be used as an indicator of disease stage 
prior to surgery.20 Similar results were achieved by 
Henshall et al. (2001) in which AR was found to be 
expressed in more than 70% of malignant cells, but in 
the adjacent peritumoral stroma AR was found to be 
expressed at very low levels.21 This data correlated with 
higher-grade prostate cancers, poorer prognosis and a 
high possibility that the cancer would relapse following 
radical prostatectomy. Furthermore, VIA has also been 
used for quantification of AR staining in TRAMP mice. 
Their data showed that AR expression in the prostates 
of TRAMP mice was consistent with that observed in 
the human prostate. 6,13 
We measured AR staining by VIA in the ventral and 
dorso-lateral prostate lobes of non-transgenic mice 
and the results showed consistency with the visual 
assessment, i.e. the average AR score in the ventral lobe 
was higher than in the dorso-lateral lobes. Concordance 
between VIA and visual scoring of AR levels was also 
achieved in intact TRAMP mice with microscopic 
lesions, with the exception of mice exhibiting PD 
adenocarcinoma, in which AR was heterogeneously 
expressed. The main inconsistency between VIA and 
visual measurement in PD adenocarcinoma either 
in microscopic lesions or in macroscopic tumours 
pertained to the percentage of positive AR staining. 
Visual scoring calculates the percentage of positively 
Med J IndonesMurti et al.12
stained brown nuclei per field of image regardless of 
the intensity of the staining (i.e. either weak, moderate 
or strong), whereas, VIA measures the intensity of 
positively stained nuclei. The difference may explain 
why the visual scoring of AR staining were considerably 
higher than the VIA measurements in the same sections. 
In contrast to the tumours, AR quantification by VIA 
and visual scoring in benign lesions from normal, 
hyperplasia and PIN without progression to WD and 
MD adenocarcinoma was more or less consistent. In 
addition, both methods of quantification demonstrated 
higher levels of AR immunostaining in benign lesions 
and WD compared to PD adenocarcinoma. These 
findings were analogous to other studies both in the 
TRAMP model and in human prostate cancer.6,12 These 
data suggest that during tumour progression, particularly 
in advanced prostate cancer, increased genetic instability 
and the development of altered androgen sensitivity may 
have occurred.
It was fascinating to observe that in TRAMP mice 
with macroscopic tumours, quantification of AR 
staining in primary tumours of castrated TRAMP mice 
revealed higher levels of AR than in intact TRAMP 
mice. This finding indicates that castration most likely 
promotes growth of androgen sensitive prostate cells 
in the TRAMP model. This finding is consistent with 
recent evidence suggesting that castration selects 
for hyperactive AR signalling pathway in clinical 
prostate cancer, possibly by increasing the expression 
of key co-regulators that enhance AR function. In 
contrast, quantification of AR staining in metastatic 
lesions showed no difference between the intact and 
castrated TRAMP mice. The difference response of AR 
quantification between the primary tumour in intact 
and castrated TRAMP mice and their metastases could 
be associated with differences in microenvironment 
between both treatments and conditions. The underlying 
mechanism for these observations is not understood, 
but is in agreement with other reports which found 
that in the castrated state AR signalling pathways are 
already activated after castration, thereby preserving 
the role of AR through tumour progression to the 
metastatic state.22 In prostate cancer cells that are not 
subjected to AAT, AR expression is reduced or lost 
in PD cancer. However, it appears that AR regulated 
signalling pathways are re-activated during prostate 
cancer progression to metastatic disease.12,15
Video image analysis has been used by many studies 
to predict the outcome of AAT.9,11,19 Using AR 
immunostaining with computer-assisted VIA techniques, 
we measured quantitative differences in AR expression in 
various prostate lesions. Video image analysis can only 
be an objective device if it used consistently and with an 
appreciation of its inherent errors. The processes in VIA 
involves several basic steps, in which every step must 
be performed as consistently and carefully as possible. 
The critical component is to set up optimal thresholds for 
every specimen and to use consistent criteria. It is often 
impossible to adjust the threshold perfectly due to the 
highly heterogenous nature of some specimens making 
the threshold setting a major source of error. In this study, 
we attempted to minimize the effect of the threshold 
setting by repeating the measurement with multiple 
threshold setting and in some cases, using a second person 
with experience in VIA to confirm the threshold setting. 
The main consequence of threshold setting is to alter the 
assessment of AR staining intensity, which could explain 
differences between VIA and visual scoring of AR levels. 
In this study we observed that AR was also expressed 
in the cytoplasm rather than nucleus of the stromal 
compartment of the TRAMP prostate. Although there 
is not much data to explain whether these observations 
are correlated to prostate tumour development or 
progression, it is possible that AR expression in the 
stroma adjacent to tumours in localised prostate cancer 
influences disease progression.20,21  It is plausible that 
stromal components in the normal prostate confer a 
predilection for tumorigenesis. A specific interaction 
between cancer cells and their microenvironment is 
required for prostate cancers to progress to metastatic 
and castrate resistant disease. The prostatic stroma, 
including extracellular matrix appears to be involved 
with endocrine, autocrine and paracrine mechanisms 
in the regulation of cancer progression.23,24 Further 
elucidation of the molecular mechanisms underlying the 
interactions between tumour cells and the surrounding 
stroma and the role of AR in regulating the stromal 
interactions may result in a better understanding of 
prostate cancer progression and lead to improvements 
in therapeutic management of this disease. 
Taken together, all the data from our findings based 
on the quantification of AR expression levels and 
other studies support the concept that AR signalling 
pathways are still utilised or up-regulated in cancer 
cells that regrow after castration. It appears that the 
activation of androgen-regulated genes in a castrate 
state is adequate to sustain tumour growth. 4,22,25 The 
increase in AR protein levels in tumour cells following 
castration could sensitise the tumour to low levels of 
ligand. However, it is also possible that different types 
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of prostate cancer cells with stem-cell properties that are 
resistant to AAT might be present from the beginning 
of the biological history of this cancer. The AAT may 
then select and trigger the growth of an androgen 
independent population that is already present together 
with the androgen dependent cell population. 13,25 
In conclusion, the findings of this study suggest that 
similar to clinical prostate cancer, in the TRAMP model, 
prostate tumours evolve mechanisms to maintain 
AR expression and AR responsive gene pathways 
following castration thereby facilitating continued 
tumour growth. The assessment of AR staining in 
prostate cancer tissues using TMAs followed by VIA 
is a potentially powerful method to predict disease 
progression and response to hormone therapy. The 
use of TMAs comprising TRAMP tissues at different 
stages of disease progression and treatment response 
will facilitate molecular and cellular analyses.
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